Ceramides and metabolic profiles of patients with acute coronary disease: a cross-sectional study
Authors:
Open Access
- 11 December 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 14, 1177765
Abstract
Metabolic Syndrome (MS) is a rapidly growing medical problem worldwide and is characterized by a cluster of age-related metabolic risk factors. The presence of MS increases the likelihood of developing atherosclerosis and significantly raises the morbidity/mortality rate of acute coronary syndrome (ACS) patients. Early detection of MS is crucial, and biomarkers, particularly blood-based, play a vital role in this process. This cross-sectional study focused on the investigation of certain plasma ceramides (Cer14:0, Cer16:0, Cer18:0, Cer20:0, Cer22:0, and Cer24:1) as potential blood biomarkers for MS due to their previously documented dysregulated function in MS patients. A total of 695 ACS patients were enrolled, with 286 diagnosed with MS (ACS-MS) and 409 without MS (ACS-nonMS) serving as the control group. Plasma ceramide concentrations were measured by LC-MS/MS assay and analyzed through various statistical methods. The results revealed that Cer18:0, Cer20:0, Cer22:0, and Cer24:1 were significantly correlated with the presence of MS risk factors. Upon further examination, Cer18:0 emerged as a promising biomarker for early MS detection and risk stratification, as its plasma concentration showed a significant sensitivity to minor changes in MS risk status in participants. This cross-sectional observational study was a secondary analysis of a multicenter prospective observational cohort study (Chinese Clinical Trial Registry, https://www.who.int/clinical-trials-registry-platform/network/primary-registries/chinese-clinical-trial-registry-(chictr), ChiCTR-2200056697), conducted from April 2021 to August 2022.Keywords
This publication has 46 references indexed in Scilit:
- What is the best biomarker for metabolic syndrome diagnosis?Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2015
- Sphingolipid metabolites in inflammatory diseaseNature, 2014
- Coronary plaque imaging by coronary computed tomography angiographyWorld Journal of Radiology, 2014
- A Ceramide-Centric View of Insulin ResistanceCell Metabolism, 2012
- Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid–induced ceramide biosynthesis in miceJournal of Clinical Investigation, 2011
- Metabolic Syndrome and Risk of Acute Myocardial InfarctionJACC, 2010
- Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndromeAmerican Journal of Physiology-Endocrinology and Metabolism, 2009
- Metabolic Syndrome PandemicArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Ceramide: A common pathway for atherosclerosis?Atherosclerosis, 2008
- The Metabolic Syndrome: A Concept Hard to DefineArchives of Medical Research, 2005